Dexmedetomidine to Improve Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery

Not Applicable

Completed

• Conditions: Anesthesia
• Interventions: Drug: dexmedetomidine; Other: loading dose; Other: sustaining dose

• Registration Number: NCT02316236
• Lead Sponsor: Air Force Military Medical University, China

Brief Summary

The study is to observe whether dexmedetomidine could reduce agitation during emergence from general anesthesia in patients undergoing retroperitoneal laparoscopic surgery.

Detailed Description

Agitation during emergence is frequent after retroperitoneal urologic surgery. Dexmedetomidine is alpha-2 receptor agonist which shows sedative and algesic effect. In this study we will compare the effect of dexmedetomidine given by different protocols on emergence agitation.

Study Timeline

• Study First Submitted: 2014-12-08
• Study Start: 2014-12-10
• Study First Submitted QC: 2014-12-10
• Study First Posted: 2014-12-12
• Primary Completion: 2015-08-12
• Study Completion: 2015-08-13
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-25
• Last Update Posted: 2022-05-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Patients scheduled for retroperitoneal laparoscopic surgery
• Patients with written informed consent

Exclusion Criteria

• Patients with difficulty of communication
• Patients with risk of obstructive sleeping apnea syndrome

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
dexmedetomidine loading dose	loading dose	dexmedetomidine is given at load dose
dexmedetomidine sustaining dose	sustaining dose	dexmedetomidine is given at sustaining dose
dexmedetomidine loading dose	dexmedetomidine	dexmedetomidine is given at load dose
dexmedetomidine sustaining dose	dexmedetomidine	dexmedetomidine is given at sustaining dose

Primary Outcome Measures

Name	Time	Method
Richmond Score	From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour

Secondary Outcome Measures

Name	Time	Method
Time to awake	From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour	time to open eyes to verbal command
Cough score	From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour

Trial Locations

Locations (1)

Xijing Hospital; 🇨🇳 Xi'an, Shaanxi, China